34 results about "D-GLUCURONIC ACID" patented technology

This invention belongs to the field of photocrosslinking probe technology, specifically relating to a GUSB photocrosslinking probe, its preparation method, and its application. The GUSB photocrosslinking probe has the general chemical formula C0. 13 H 18 N2O6-R, wherein R is any one of the oxalic group elements or peptide bonds. The R group covalently connects the glucuronic acid recognition core and the photosensitive unit in the GUSB photocrosslinking probe, and the R group contains no more than 4 atoms, resulting in a small size and low steric hindrance. The GUSB photocrosslinking probe provided by this invention uses glucuronic acid as the recognition core, combined with a small-volume diazacyclopropane photosensitive unit and a terminal alkyne group, to achieve µM-level in-situ covalent capture of active GUSB in complex systems such as cells or tissues. The probe of this invention significantly improves positioning accuracy, sensitivity, data availability, quantification, and enrichment, while also possessing advantages such as modular synthesis, mild conditions, and strong system compatibility, effectively addressing the technical shortcomings of existing technologies that struggle to accurately obtain GUSB activity in situ under low-dose conditions.

The present application relates to the technical field of antibody conjugated drugs, in particular to a drug conjugate with sustained-release property, an antibody conjugated drug and application thereof. The drug conjugate Payload is a payload selected from a drug molecule with cytotoxicity; X is a heteroatom in the payload, selected from O or N; R4 and R5 are independently selected from hydrogen, an alkyl group or other chemical modification groups; R1, R2, R3 and R6 are independently selected from hydrogen, an amino group, a group containing an ether bond, a hydrophilic group, a halogen, an alkyl group or other chemical modification groups; and Glu is a glucuronic acid group. The present application has the advantages of achieving sustained-release effect, increasing stability, avoiding possible non-specific rupture of carbamate bonds in in-vivo circulation, improving the half-life of ADC drugs in blood circulation, reducing toxicity and increasing drug efficacy, and achieving more effective and safe treatment effect due to the sustained-release mechanism which maintains local toxin concentration in a more reasonable killing interval and reduces systemic toxic side effects.

The application discloses Ixeris sonchifolia Hance polysaccharides, a preparation method and application thereof, belongs to the technical field of plant polysaccharides, and provides polysaccharides ISP-1a and ISP-2a, wherein the ISP-1a has a molecular weight of 2086 Da and is composed of seven monosaccharides of mannose, rhamnose, glucuronic acid, glucose, galactose, xylose and arabinose; the ISP-2a has a molecular weight of 1781 Da and is composed of five monosaccharides of mannose, rhamnose, galacturonic acid, xylose and arabinose. The whole grass of Ixeris sonchifolia Hance is subjected to hot water extraction after ethanol degreasing, neutral enzyme + Sevage method is used to remove protein, macroporous resin is used for decolorization, column chromatography elution is carried out, purification is carried out, and two kinds of uniform polysaccharides are obtained after freeze-drying. The polysaccharides ISP-1a and ISP-2a have good antioxidant and lipid-lowering effects, and can be applied to the preparation of food, health products or medicines with antioxidant and lipid-lowering functions.

This invention relates to a method for identifying and detecting urinary biomarkers of whole-grain wheat intake. These biomarkers include glycine conjugates of 3,5-dihydroxybenzoic acid, sulfate conjugates of o-aminophenol, sulfate conjugates of 2-acetaminophen, sulfate conjugates of 3,5-dihydroxyphenylvaleric acid, glucuronic acid conjugates of o-aminophenol, or glucuronic acid conjugates of 2-acetaminophen. The invention also relates to a high-throughput screening method for urinary biomarkers of whole-grain wheat intake. A whole-grain wheat dietary intervention experiment was designed, and through comparative analysis of human urinary metabolic profiles, non-targeted metabolomics technology was used to screen for urinary metabolic biomarkers of whole-grain wheat, providing a method for accurately assessing whole-grain wheat intake.

The application discloses a rehmannia polysaccharide, a preparation method thereof and application of the rehmannia polysaccharide in preparation of a medicine for preventing and treating kidney injury caused by cisplatin. The rehmannia polysaccharide contains the following monosaccharides in percentage by mass: rhamnose (Rha) 10.265%-14.963%, glucuronic acid (GlcA) 0.514%-0.904%, galacturonic acid (GalA) 35.784%-40.596%, glucose (Glc) 3.128%-5.048%, galactose (Gal) 37.892%-41.438% and arabinose (Ara) 3.869%-4.865%. The structure of the rehmannia polysaccharide is clear, and the rehmannia polysaccharide shows a significant improvement effect on cisplatin nephrotoxicity through cell experiments and animal experiments, and has important value for developing a new and effective prevention and treatment product of cisplatin-induced acute kidney injury.

The invention relates to beekeeping, in particular to a process for producing royal jelly.The process, according to the invention, includes the introduction into the breeding family of frames equipped with qeen cells with transferred larvae and the daily feeding of the nurse bees, in the absence of a maintenance honey flow, with a mixture of sugar syrup and a biostimulator, for 3 days, after which the frames are removed from the hive to collect the royal jelly, and the procedure is repeated twice, at the same time the biostimulator is an aqueous solution containing: D-glucuronic acid, potassium hydroxide, choline chloride and water.

This invention discloses a method for preparing a highly water-resistant, glue-free, synergistically cross-linked bamboo-based board, comprising the following steps: preparing polyphenol-modified bamboo powder; adding glucuronic acid solution dropwise to the polyphenol-modified bamboo powder, reacting at 50℃~65℃, then adding citric acid solution, and reacting again to obtain cross-linked modified bamboo powder; adjusting the moisture content of the cross-linked modified bamboo powder to 8wt%~12wt%, and pre-pressing it into a blank; covering the upper and lower surfaces of the blank with a release film and a steel plate respectively, then placing it in a flatbed hot press, and performing segmented pressing molding at 155℃~165℃ to obtain the highly water-resistant, glue-free, synergistically cross-linked bamboo-based board. The resulting board requires no traditional adhesives, possesses high mechanical strength, excellent water resistance, and dimensional stability, and the process is mild with green raw materials, making it suitable for the field of green building materials and providing a new approach for the efficient utilization of bamboo resources.

This invention provides an extract of Astragalus complanatus and its preparation method. The extract comprises the following raw materials in molar percentages: Astragalus complanatus polysaccharide 31.79%–84.74%, protein 6.56%–34.35%, uronic acid 4.07%–27.11%, polyphenols 3.76%–10.83%, rhamnose 0.4%–3.35%, arabinose 0.97%–22.55%, xylose 0.30%–25.28%, mannose 0–58.37%, glucose 0–1.27%, galactose 17.38%–43.03%, and glucuronic acid 0.58%–55.71%. The Astragalus complanatus extract of this invention has the advantages of high purity, clearly defined active ingredients, and uniform stability. In vivo efficacy experiments using zebrafish have shown that the Astragalus complanatus extract of this invention has significant therapeutic effects on fatty liver, non-alcoholic steatohepatitis, alcoholic steatohepatitis, and hyperlipidemia.

The application relates to the technical field of washing and protecting products, in particular to a traditional Chinese medicine soothing liquid for nourishing the scalp and a preparation method thereof. The traditional Chinese medicine soothing liquid comprises a traditional Chinese medicine extract and an additive. The preparation method of the traditional Chinese medicine soothing liquid is as follows: S1, pulverizing radix polygoni multifidi, biota orientalis and rhizoma alocasia, adding an ethanol solution to heat and reflux extraction to obtain medicinal liquid A; pulverizing herba polygoni avicularis, radix bupleuri, herba cynomorii, semen abrus and semen euryales, adding water to heat and reflux extraction to obtain medicinal liquid B, and combining medicinal liquid A and medicinal liquid B to obtain a traditional Chinese medicine extract; S2, adding an additive to the traditional Chinese medicine extract, stirring and uniformly mixing to prepare the traditional Chinese medicine soothing liquid; the additive comprises fucus vesiculosus extract, galacturonic acid, glucuronic acid, a humectant, a surfactant and a preservative; and the traditional Chinese medicine soothing liquid has the advantages of improving the efficacy of the traditional Chinese medicine composition on the scalp improvement.

This invention relates to an aqueous emulsion comprising: (A) an ester of fatty acids and polyglycerol having 16 to 22 carbon atoms, an ester of fatty acids and glycerol having 16 to 22 carbon atoms, and a monohydric alcohol having 16 to 22 carbon atoms; (B) a compound having at least two hydroxyl groups and an alkyl group having 16 to 22 carbon atoms and having no phosphorus atoms, or a salt thereof, wherein component (B) is different from component (A); and (C) a cellulose thickener and / or a polysaccharide thickener comprising glucose, glucuronic acid, and rhamnose as the main chain of constituent monosaccharides.

This invention relates to the field of biotechnology, specifically to an inositol oxidase mutant and its application in the production of glucuronic acid. The inositol oxidase mutant provided by this invention is obtained by point mutation of the amino acid sequence shown in the wild-type inositol oxidase. Compared with the wild-type enzyme, the inositol oxidase mutant constructed by this invention exhibits a significant improvement in catalytic efficiency. Furthermore, this invention also provides an engineered strain with site-directed mutagenesis and knockout of the UxaC gene in the chassis cell genome. This strain exhibits higher catalytic activity towards the substrate, with a catalytic efficiency increased by 74.44% compared to the wild-type enzyme. Even at high substrate concentrations, the conversion rate can still reach over 92.09%, with a production intensity as high as 13.23 g / L / h. It possesses extremely strong substrate tolerance and production intensity, significantly reducing the production cost of glucuronic acid and demonstrating significant industrial application potential.

Embodiments of the present invention provides recombinant systems, methods, and compositions for the biological production of Testosteronan (Testan), a linear α-(1→4)-linked glucuronic acid–N-acetylglucosamine polysaccharide. Microbial hosts engineered to express full-length CtTS, N-terminal truncation variants (including d64-CtTS), or the Pseudomonas CIPTS homolog synthesize high–molecular-weight Testan (≥800 kDa) with low polydispersity. Structural analysis by ¹H NMR and 2D HSQC demonstrates that all recombinant enzymes produce Testan that is chemically indistinguishable from native polymer. Purification using ultrafiltration and strong-anion exchange chromatography yields highly defined molecular-weight fractions, including monodisperse populations (PDI ~1.02). The invention further provides sulfated derivatives of Testan produced via aqueous sulfation methods, as well as Testan and functionalized Testan compositions useful for chromatographic stationary phases, biomaterial scaffolds, and chemically modifiable polymer platforms. These systems provide the first scalable, fermentation-based production methods for Testan and Testan-derived materials.

The present application provides a kind of arabinoxylan with beneficial activity prepared with corn skin as raw material.The arabinoxylan is composed of xylose, arabinose, glucose, galactose, rhamnose, mannose, glucuronic acid, galacturonic acid, fucose, ribose according to the molar ratio of 104.6:82.6:21.0:16.8:8.9:5.1:4.3:1.6:1.3:1, and the molecular weight is 2.51-10 kDa.The present application uses xylanase Scxyn22 to prepare arabinoxylan with specific molecular weight distribution and monosaccharide composition, the molar ratio of arabinose / xylose reaches 0.79, has unique apparent viscosity and antioxidant activity, can promote the proliferation of lactobacillus fermentum and lactobacillus casei, and can be applied in food field as food stabilizer, food thickening agent and new prebiotic.

This invention relates to the field of pharmaceutical and chemical intermediates technology, and discloses a novel class of substituted phenylethyl-O-β-D-glucuronide compounds. These compounds are generated using substituted phenylethanol as a substrate and 1-fluoro-D-glucuronic acid as a glycosyl donor, catalyzed by β-glucuronyltransferase derived from *E. coli*. The process yield can reach over 95%, and the reaction conditions are mild and environmentally friendly. Substituted phenylethyl-O-β-D-glucuronide can be efficiently used for the determination of β-glucuronidase activity, and its applications are wide-ranging and reliable. The product can meet the needs of pharmaceutical, food, and other fields for β-glucuronidase activity control. It can be used for enzyme activity detection in the auxiliary diagnosis of clinical diseases, and also for enzyme quality control in fruit juice clarification processes in the food industry, drug precursor activation, and glycan structure analysis in the biopharmaceutical field. The product structure has been verified to be accurate by mass spectrometry and 1H NMR spectroscopy, and enzymatic hydrolysis experiments have confirmed its reliable application.

This invention relates to the field of microbial technology, and particularly to a free extracellular polysaccharide of *Lactobacillus paracasei* with immunostimulatory activity, its preparation, and its application. This invention provides an immunostimulatory extracellular polysaccharide of *Lactobacillus paracasei*, which is a free extracellular polysaccharide with a molecular weight of approximately 7.66 × 10⁻⁶. 5 Da contains the following monosaccharides: glucose content of 98.90%, glucuronic acid content of 0.61%, and mannose content of 0.49%. The main chain is composed of (1→4)-α-D-glucopyranosyl groups, and the side chains are composed of (1→6)-α-D-glucopyranosyl groups and (1→3)-α-D-glucopyranosyl groups, making it a novel polysaccharide. It promotes the proliferation and secretion of IL-1β, TNF-α, IL-6, and IL-10 by RAW264.7 cells. Furthermore, this invention provides a method for preparing this polysaccharide, which produces and achieves high yields, laying the foundation for its application.

This invention belongs to the field of plant polysaccharide technology, specifically relating to a Ganoderma lucidum solid-state fermented wheat pericarp polysaccharide with lipid-lowering activity and its preparation method. The polysaccharide is composed of fucose, arabinose, galactose, glucose, xylose, mannose, galacturonic acid, and glucuronic acid, with molar percentages of 2.14%, 13.68%, 14.66%, 21.50%, 31.43%, 2.42%, 7.86%, and 6.31%, respectively, and an average molecular weight of 10.00×10³–15.00×10³ Da, preferably 11.05×10³ Da. This invention utilizes Ganoderma lucidum to ferment wheat pericarp in a solid state, followed by ultrasonic-assisted hot water extraction to crudely extract the polysaccharide. The crude polysaccharide is then purified by anion exchange column and dextran gel column chromatography. The resulting fermented wheat pericarp polysaccharide effectively improves lipid deposition, exhibits significant lipid-lowering activity, and has high safety.

The present application relates to a glucuronic acid triterpene saponin and its use in the preparation of analgesic drugs. The glucuronic acid triterpene saponin of the present application can be a naturally occurring organic compound or a synthetic organic compound, has strong analgesic activity, and is used as an active ingredient to prepare an analgesic drug composition with a pharmaceutically acceptable carrier or excipient.

This invention discloses an acidic polysaccharide from Gynostemma pentaphyllum, AGPA12, its purification and extraction method, and its application in the preparation of anti-pancreatic cancer drugs. AGPA12 is mainly composed of mannose, glucuronic acid, rhamnose, glucose, galactose, and fucose, with a molar ratio of 1.05:1.74:6.29:1.40:69.48:19.03. The polysaccharide was extracted using an α-amylase-assisted water extraction and alcohol precipitation method, and purified by DEAE-Sepharose FF ion exchange chromatography and Sepharose CL6B gel chromatography. In vitro experiments showed that AGPA12 had significant inhibitory effects on the proliferation and migration of human pancreatic cancer AsPC1 cells, and its mechanism was related to the regulation of the MAPK signaling pathway and the expression of apoptosis-related proteins. This invention provides a new approach for the development of Gynostemma pentaphyllum polysaccharides and their application in anti-pancreatic cancer drugs.

The application belongs to the technical field of plant polysaccharides, and specifically discloses a morindae polysaccharide, a preparation method thereof and a pharmaceutical use of the morindae polysaccharide in treating inflammation. Monosaccharides in the morindae polysaccharide include mannose, glucuronic acid, galacturonic acid, glucose and arabinose, and the molar ratio is 0.5-0.6:0.3-0.5:1-2:1-2:0.5-1.5. The morindae polysaccharide provided by the application is a new type of structural uniform polysaccharide which is first isolated from morindae stems, has a slightly acidic pH value, clear monosaccharide composition, determined molecular weight and clear glycosidic bond linkage mode, has an anti-inflammatory effect and is expected to be developed into a new anti-inflammatory drug. The preparation process is mild, simple to operate and environmentally friendly.

This invention belongs to the field of pharmaceutical preparations and food additives, specifically relating to a curcumin composition, its preparation method, and its applications. The composition comprises curcumin and a solubilizing factor, wherein the solubilizing factor is selected from at least one of maltitol, isoleucine, glucuronic acid, glucosamine, methionine, and alanine; the molar ratio of curcumin to the solubilizing factor is 1:2 to 1:20; in the composition, curcumin is dispersed in an amorphous state within the solubilizing factor matrix. The solubility of this composition in water is increased by 270 to 500 times compared to pure curcumin, and its thermal stability is significantly improved. The preparation method utilizes the principle of antisolvent precipitation: an organic curcumin solution is slowly added dropwise to an aqueous solution of the solubilizing factor; the precipitate is obtained by filtration and drying. The process is simple and yields a high rate. This composition can be used to prepare pharmaceutical preparations, functional foods, or health products.

This invention discloses a method for preparing xanthan gum oligosaccharides by hydrolyzing xanthan gum. The method is as follows: 10-15g of xanthan gum is added to 0.2-0.8M HCl (1 L), followed by 10-25mL of 30% H2O2. The mixture is stirred and hydrolyzed in an 80℃ water bath for 24-48 hours. After hydrolysis, alkali is added for neutralization, and the mixture is concentrated by rotary evaporation. High molecular weight polysaccharides are removed by adding anhydrous ethanol to achieve a final concentration of 60-75%. Anhydrous ethanol is then added again to achieve a final concentration of 80-90% to obtain crude xanthan gum oligosaccharides. Finally, the mixture is dialyzed to remove salts and obtain xanthan gum oligosaccharides. The degree of polymerization of xanthan gum oligosaccharides ranges from 2 to 9, and the monosaccharide composition is glucose, mannose, and glucuronic acid in a molar ratio of [1.5-2.5]:[1.2-1.9]:[0.7-1.1]. Xanthan gum oligosaccharides can regulate the composition of intestinal flora and improve blood glucose homeostasis, especially by increasing the abundance of butyrate-producing bacteria. They are suitable for people with hyperglycemia and have good application prospects and market value.

Described herein are processes and enzymes for the enzymatic production of glucaric acid from glucuronic acid, and more specifically the enzymatic production of substituted glucaric acid from substituted glucuronic acid. Advantageously, the process and enzymes described herein make preferential use substituted glucuronic acid obtained from natural sources, such as underutilized hemicellulose stream from wood and agricultural biorefineries, to produce substantially enantiomerically pure substituted D-glucaric acid.

The present invention provides a topical skin preparation composition containing a heparin-like substance that has an excellent effect in improving the skin barrier function. [Solution] A topical skin preparation composition containing a heparin-like substance (A) in which the proportion of disaccharide units consisting of C2-sulfated D-glucuronic acid and C4,C6-disulfated N-acetyl-D-galactosamine is 7 to 22 mol%.

The invention relates to beekeeping, in particular to a process for raising queen bees.The process, according to the invention, comprises forming a family of nurse bees by removing the queen and the combs with uncapped brood, introducing a frame with transferred larvae into the nest and feeding the nurse bees with a mixture of sugar syrup and aqueous solution of D-glucuronic acid and choline chloride, daily for 5 days, from the introduction of the frame with transferred larvae up to the capping of the qeen cells.

This invention discloses a *Equisetum hyemale* polysaccharide, its preparation method, and its applications, belonging to the field of natural polysaccharide technology. Using *Equisetum hyemale* as raw material, the polysaccharide was extracted using a hot water ultrasonic-assisted extraction method. Through single-factor and orthogonal experiments, the optimal process was determined to be a material-to-liquid ratio of 1:20 g / mL, a temperature of 70℃, an ultrasonic power of 400 W, and an extraction time of 50 min. Under these conditions, the polysaccharide yield reached 13.05%. The crude polysaccharide was deproteinized using the Sevage method and purified by DEAE-52 cellulose column and Sephadex G-100 gel column to obtain purified *Equisetum hyemale* polysaccharide (DEPS) with homogeneous components. Physicochemical characterization showed that the DEPS had a total sugar content of 55.36%, a molecular weight of 67.61 kDa, and was composed of mannose, glucuronic acid, glucose, and fucose. It lacked a triple helix structure and contained typical polysaccharide functional groups and pyranose ring structures. In vitro experiments showed that DEPS exhibited the highest scavenging rates of DPPH, ABTS, and hydroxyl radicals, reaching 87.54%, 97.52%, and 97.5%, respectively, with its antioxidant activity showing a concentration-dependent effect. This invention features a simple process and high yield, producing a high-quality Equisetum hyemale polysaccharide.

This invention relates to a crosslinking agent for improving the thermal stability of amino substrates and its application. The crosslinking agent for improving the thermal stability of amino substrates is one or more of glucuronic acid, galacturonic acid, glucuronide, methyl glucuronide, and methyl galacturonide. It improves substrate performance by reacting with the amino substrate through Maillard reactions or amidation reactions via its contained active aldehyde, carboxyl, or ester groups. This crosslinking agent exhibits significant crosslinking effect, good biocompatibility, and high permeability.

This invention discloses a purified caraway polysaccharide, its preparation method, and its applications. Using caraway seeds as raw material, the invention employs an ultrasound-assisted enzymatic extraction method to extract the polysaccharide, which is then further purified to obtain purified caraway polysaccharide. Analysis and identification show that this purified polysaccharide is a heteropolysaccharide composed of fucose, arabinose, rhamnose, galactose, glucose, xylose, mannose, galacturonic acid, and glucuronic acid. The purified caraway polysaccharide extracted in this invention exhibits significant inhibitory effects on DPPH, OH, ABTS, α-glucosidase, and α-amylase, and can significantly inhibit the proliferation of HepG2 and SNU449 liver cancer cells and induce apoptosis. Therefore, it can be used to prepare functional products with antioxidant, hypoglycemic, or anti-liver cancer effects, thereby improving the utilization value of caraway.

This invention provides a novel polysaccharide extracted from dried plum (Prunus mume), its preparation method, and its uses. The monosaccharide molar fraction in the Prunus mume polysaccharide is as follows: 0.5%-1.0 mol% fucose, 1.0%-2.0 mol% rhamnose, 35%-37 mol% arabinose, 15%-17 mol% galactose, 9.0%-11 mol% glucose, 2.0%-3.0 mol% xylose, 6%-8 mol% mannose, 23%-25 mol% galacturonic acid, and 1.0%-2.0 mol% glucuronic acid. The Prunus mume polysaccharide isolated and purified by this invention exhibits excellent antioxidant activity. Furthermore, based on the complex acidic heteropolysaccharide structure of the Prunus mume polysaccharide, especially its high proportion of uronic acid and branched structure, it possesses potential for various biological activities and has extremely high industrial utilization value.

Embodiments of the present invention provides recombinant systems, methods, and compositions for the biological production of Testosteronan (Testan), a linear α-(1→4)-linked glucuronic acid–N-acetylglucosamine polysaccharide. Microbial hosts engineered to express full-length CtTS, N-terminal truncation variants (including d64-CtTS), or the Pseudomonas CIPTS homolog synthesize high–molecular-weight Testan (≥800 kDa) with low polydispersity. Structural analysis by ¹H NMR and 2D HSQC demonstrates that all recombinant enzymes produce Testan that is chemically indistinguishable from native polymer. Purification using ultrafiltration and strong-anion exchange chromatography yields highly defined molecular-weight fractions, including monodisperse populations (PDI ~1.02). The invention further provides sulfated derivatives of Testan produced via aqueous sulfation methods, as well as Testan and functionalized Testan compositions useful for chromatographic stationary phases, biomaterial scaffolds, and chemically modifiable polymer platforms. These systems provide the first scalable, fermentation-based production methods for Testan and Testan-derived materials.

This invention discloses a β-glucuronidase and its enzymatic hydrolysis method for preparing baicalin and glucuronolactone, belonging to the field of genetic engineering technology. The amino acid sequence of this β-glucuronidase is obtained by mutation of the amino acid sequence shown in SEQ ID NO.1, specifically a mutation at amino acid position 296 and / or amino acid position 329 of the amino acid sequence shown in SEQ ID NO.1. The mutated β-glucuronidase mutant obtained by this invention exhibits higher enzyme activity and stronger hydrolytic activity towards the substrate baicalin, thereby effectively improving reaction efficiency and substrate conversion rate in the hydrolysis of baicalin to produce baicalin and glucuronic acid.